Hester Biosciences’ record carries a clean audit trail across seven years, but three things demand attention: a wholly owned African subsidiary has delayed principal of ₹22.76 crore and interest of ₹8.54 crore on a Gates Foundation term loan, crystallising the risk under an existing ₹132.77 crore parent guarantee; trade receivables have stretched to 105 days with a ₹6.5 crore bad-debt write-off; and a Gandhi-family-controlled board faces recurring public-institutional dissent while the CFO role has turned over three times in five years.
Key findings
- Receivable days climbed to 105 while the auditor flagged trade receivables as a Key Audit Matter across multiple years, and the company wrote off ₹6.5 crore of bad debts
Major- Receivable days rose from 86 in FY25 to 105 in FY26, a 22% year-on-year increase. The CFO disclosed a ₹6.5 crore bad-debt write-off in the Q4 FY26 earnings call and attributed the high receivables to Q4 sales being more than a third of the annual total. The independent auditor identified the carrying value of trade receivables as a Key Audit Matter, an area needing the most judgement, in the standalone FY2021 and FY2023 financial statements and in the consolidated FY2024 statements. - A Gandhi-family-controlled board faces recurring public-institutional dissent on promoter resolutions, while the CFO role turned over three times in five years
Major- Public-institutional holders voted 99.24% against the re-appointment of CEO Rajiv Gandhi at the postal ballot concluded 9 March 2026, and 99.75% against the remuneration revision of his daughter Priya Gandhi at the AGM on 29 August 2024. The CFO position changed three times in five years, and the Secretarial Audit Report for FY26 noted the latest change was carried out through a circular resolution instead of a Board meeting resolution. On 14-15 May 2026, two promoter-group members requested reclassification to the public category under SEBI Regulation 31A. - CARO reports flagged borrower repayment irregularities on company-granted loans in FY22-FY24, but the pattern cleared in FY25-FY26
Minor- In FY23, CARO reported that borrowers had not repaid principal as stipulated and had not been regular in payment of interest, with interest net of TDS amounting to ₹0.47 crore overdue for more than ninety days and a further ₹0.51 crore unpaid till the report date. In FY24, borrowers repaid outstanding interest for the previous two financial years 2021-22 and 2022-23 with delays of 754 days and 361 days respectively. The statutory auditor issued an unqualified opinion on both standalone and consolidated financial statements for every year from FY20 through FY26. - The group operates through a layered chain of African and Asian subsidiaries, with a joint venture that has remained unaudited for years
Minor- As of 31 March 2026, the group comprised three direct subsidiaries, one step-down subsidiary, and a 50% joint venture, Thrishool Exim Limited in Tanzania. The joint venture has been unaudited every year since its acquisition in FY22, with its financial statements certified by management; the auditor stated these were not material to the group. During FY26, the company sold a 43.81% stake in Texas Lifesciences to a promoter-affiliated entity, reducing its holding to 11%. - The main contingent exposure is the USD 14 million corporate guarantee for the Tanzanian subsidiary, while disputed tax demands remain small
Minor- The outstanding corporate guarantee to subsidiaries stood at 132.77 crore as of 31 March 2026, securing term loans of ₹113.8 crore drawn by Hester Biosciences Africa Limited. Disputed statutory dues comprised Income Tax of 0.11 crore and GST demands totalling 3.8 crore, all pending at appellate authorities with no provision made. - Operating cash flow has strengthened to cover profits and dividends, while borrowing costs capitalised into CWIP have masked the true interest burden
Clean- Cumulative operating cash flow of ₹267.19 crore exceeded cumulative profit of ₹209.70 crore over FY21-FY26. Borrowing costs capitalised into CWIP totalled ₹5.66 crore in FY26, down from a peak of ₹10.17 crore in FY23 as the BSL-3 and Fill-Finish facilities were capitalised during the year. Free cash flow was ₹64.53 crore in FY26, exceeding dividend outflows.
What to watch
- Gates Foundation waiver or restructuring. Management stated a waiver or restructuring of the missed December 2025 payment “materialised after the balance sheet date” of 31 March 2026.
- Promoter reclassification. Outcome of requests by Bela Gandhi and Ravin Gandhi to reclassify from promoter to public category under SEBI Regulation 31A, submitted 14-15 May 2026.
- Priya Gandhi re-appointment. Vote on her appointment as Executive Director for three years from 28 October 2026 at the 39th AGM, notice dated 8 July 2026.
- BIRAC grant release. Pattern and quantum of the ₹50 crore government grant release to the P&L, now that the facility has been put to use in FY2026.
- Receivable days and write-offs. Movement in receivable days and any further bad-debt provisions in the FY27 annual report, following the ₹6.5 crore write-off disclosed in the Q4 FY26 call.
Bottom line: This is a disclosed and audited record with strengthening cash conversion and a clean audit opinion across seven years. The risk concentrates in one place: the African subsidiary, whose ₹132.77 crore guarantee now links the standalone balance sheet to a much larger pool of consolidated debt. Watch whether the Gates Foundation restructures that obligation, and read the receivables line alongside the promoter-governance votes, both will signal whether the collection and control environment is tightening or drifting.